Arena Pharmaceuticals Inc (ARNA)
PHARMACEUTICAL PREPARATIONS
- Headquarters
- United States
- Employees
- 448
- Market Cap
- $6.2B
About Arena Pharmaceuticals Inc
Arena Pharmaceuticals is a biotechnology company targeting G-protein-coupled receptors. The company has one internally discovered drug, lorcaserin, which has been approved and is marketed in the U.S. and South Korea to target weight management. It is commercialized under the brand name Belviq. The company is collaborating with Eisai to market Belviq in other countries. It has a presence in Europe through its Swiss subsidiary, Arena GmbH. The company's pipeline contains drugs targeting autoimmune diseases, vascular diseases, thrombotic diseases, dementia-associated psychosis, nervous system issues, and pain.
SentiSense also tracks daily options readings for Arena Pharmaceuticals Inc: IV rank, put/call percentile, 25-delta skew, open-interest walls, and unusually active contracts, each measured against the stock's own history. Sign in to view them.
Arena Pharmaceuticals Inc stock analysis, sentiment tracking, and market intelligence on SentiSense.